bremelanotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
==== Serotonergic pathway regulation ==== KOR activation suppresses serotonergic signaling through multiple mechanisms, including regulation of the serotonin transporter (SERT) via intracellular kinase cascades. Dynorphin, released from local GABAergic neurons within reward-related regions, can bind to KORs expressed on serotonergic terminals projecting from the DRN to regions such as NAcc, prefrontal cortex, and other limbic structures associated with mood regulation. Agonist-induced binding to these receptors triggers rapid, concentration-dependent upregulation of SERT function through CaMKII and Akt. This increased trafficking of SERT to the plasma membrane, enhances serotonin reuptake via p38 MAPK-mediated recruitment, coupled with increased phosphorylation of the transporter protein, reducing serotonin's functional availability to the postsynaptic 5‑HT1A and other 5‑HT receptor subtypes. Beyond depleting serotonin levels, KOR agonism directly interferes with the signaling efficacy of 5-HT1A receptor G-protein through competition as both receptors are coupled to Gi/0. The presence of KOR agonists depletes the available pool of the heterotrimeric G-proteins and the receptor's mutant variant I135L which has a high basal activity inhibits signaling mediated by the 5-HT1A. In the NAcc, stress-dependent upregulation of postsynaptic 5-HT1B receptors co-expressed on direct pathway neurons expressing prodynorphin is an additional downstream mechanism.
Proglumide, sold under the brand name Milid, is a drug that inhibits gastrointestinal motility and reduces gastric secretions. It acts as a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. It was used mainly in the treatment of stomach ulcers, although it has now been largely replaced by newer drugs for this application. An interesting side effect of proglumide is that it enhances the analgesia produced by opioid drugs, and can prevent or even reverse the development of tolerance to opioid drugs. This can make it a useful adjuvant treatment to use alongside opioid drugs in the treatment of chronic pain conditions such as cancer, where opioid analgesics may be required for long periods and development of tolerance reduces clinical efficacy of these drugs. Proglumide has also been shown to act as a δ-opioid receptor (DOR) agonist, which may contribute to its analgesic effects. However, other studies show that proglumide has low affinity to the μ-opioid receptor (MOR) and the κ-opioid receptor (KOR) (13% of MOR and 17% of KOR occupancy at 100 μM), but no affinity to DOR. It is questionable whether this is clinically significant, since the concentration they used was very high, and the occupancies were low even at that point. Proglumide also works as a placebo effect amplifier for pain conditions. When injected visibly to a subject, its analgesic effect is bigger than a similarly administered placebo.
== Children == Pediatric MASLD was first reported in 1983. It is the most common chronic liver disease among children and adolescents since at least 2007, affecting 10 to 20% of them in the US in 2016. MASLD is associated with metabolic syndrome, which is a cluster of risk factors that contribute to the development of cardiovascular disease and type 2 diabetes mellitus. Studies have demonstrated that abdominal obesity and insulin resistance, in particular, are significant contributors to the development of MASFLD. Coexisting liver diseases, such as hepatitis C and cardiovascular diseases such as atherosclerosis, are also associated with an increased risk of MASFLD. Some children were diagnosed as early as two years old, with a mean age of diagnosis between 11 and 13 years old. The mean age is usually above 10 years, as children can also report non-specific symptoms and are thus difficult to diagnose for MASLD. Boys are more likely to be diagnosed with MASLD than girls. Overweight, or even weight gain, in childhood and adolescence, is associated with an increased risk of MASLD later in life, with adult MASLD predicted in a 31-year follow-up study by risk factors during childhood including BMI, plasma insulin levels, male sex, genetic background (PNPLA3 and TM6SF2 variants) and low birth weight, an emerging risk factor for adulthood MASLD. In a study, simple steatosis was present in up to 45% in children with a clinical suspicion of MASLD.
Sources: en.wikipedia.org
=== Carrier gas selection and flow rates === Typical carrier gases include helium, nitrogen, argon, and hydrogen. Which gas to use is usually determined by the detector being used, for example, a DID requires helium as the carrier gas. When analyzing gas samples the carrier is also selected based on the sample's matrix, for example, when analyzing a mixture in argon, an argon carrier is preferred because the argon in the sample does not show up on the chromatogram. Safety and availability can also influence carrier selection. The purity of the carrier gas is also frequently determined by the detector, though the level of sensitivity needed can also play a significant role. Typically, purities of 99.995% or higher are used. The most common purity grades required by modern instruments for the majority of sensitivities are 5.0 grades, or 99.999% pure meaning that there is a total of 10 ppm of impurities in the carrier gas that could affect the results. The highest purity grades in common use are 6.0 grades, but the need for detection at very low levels in some forensic and environmental applications has driven the need for carrier gases at 7.0 grade purity and these are now commercially available. Trade names for typical purities include "Zero Grade", "Ultra-High Purity (UHP) Grade", "4.5 Grade" and "5.0 Grade". The carrier gas linear velocity affects the analysis in the same way that temperature does (see above). The higher the linear velocity the faster the analysis, but the lower the separation between analytes.
There are large wealth disparities, and many post-soviet economies are described as oligarchic. Since the dissolution of the Soviet Union, annual polling by the Levada Center has shown that over 50% of Russia's population regretted this event, with the only exception to this being in 2012 when support for the Soviet Union dipped below 50 percent. A 2018 poll showed that 66% of Russians regretted the fall of the Soviet Union, setting a 15-year record, and the majority of these regretting opinions came from people older than 55. In 2020, polls conducted by the Levada Center found that 75% of Russians agreed that the Soviet era was the greatest era in their country's history. According to the New Russia Barometer (NRB) polls by the Centre for the Study of Public Policy, 50% of Russian respondents reported a positive impression of the Soviet Union in 1991. This increased to about 75% of NRB respondents in 2000, dropping slightly to 71% in 2009. Throughout the 2000s, an average of 32% of NRB respondents supported the restoration of the Soviet Union. In a 2021 poll, a record 70% of Russians indicated they had a mostly/very favourable view of Joseph Stalin. In Armenia, 12% of respondents said the USSR collapse did good, while 66% said it did harm. In Kyrgyzstan, 16% of respondents said the collapse of the USSR did good, while 61% said it did harm. In a 2018 Rating Sociological Group poll, 47% of Ukrainian respondents had a positive opinion of Soviet leader Leonid Brezhnev, who ruled the Soviet Union from 1964 to 1982, while viewing Lenin, Stalin, and Gorbachev very negatively.
=== Acquired hypofibrinogenemia === Acquired hypofibrinogenemia is a deficiency in circulating fibrinogen due to excessive consumption that may occur as a result of trauma, certain phases of disseminated intravascular coagulation, and sepsis. It may also occur as a result of hemodilution as a result of blood losses and/or transfusions with packed red blood cells or other fibrinogen-poor whole blood replacements. The low fibrinogen level in hemorrhagic fever caused by crimean-congo hemorrhagic fever virus is associated with high mortality rate.
==== European Chips Act ==== In February 2022, the European Union introduced its own European Chips Act initiative. The background of the initiative would be the objective of European strategic autonomy. The EU's initiative puts forward subsidies of 30 billion euros to encourage manufacturing of semiconductors in the EU. The US company Intel is one beneficiary of the initiative. The US and European chips acts raise concerns of protectionism and a risk of a subsidies "race to the bottom".
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.